Clinical Trials

Classical hematologyMyeloidOther hematologic neoplasm

282 enrolled 11 charts

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01787487 2026-03-31

Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Phase 2 Completed

121 enrolled

Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Primary Myelofibrosis

NCT05376111 2026-03-19

Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients

LymphoidOther hematologic neoplasm

28 enrolled

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06220162 2026-03-19

VAC Regimen for AML Patients Who Failed to Response to VA Regimen

32 enrolled

Leukemia, Myeloid, Acute

NCT06379360 2026-03-19

Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients

77 enrolled

Leukemia, Myeloid, Acute

NCT06557421 2026-03-13

STOP VEN

Phase 2 Not yet recruiting

Leukemia, Myeloid, Acute

NCT07471841 2026-03-13

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

25 enrolled

Phase 2 Not yet recruiting

Leukemia, Myeloid, Acute

NCT07463768 2026-03-11

MIVONU

60 enrolled

Leukemia, Myeloid, Acute

NCT03226418 2026-03-10

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

Phase 2 Completed

75 enrolled 14 charts

Leukemia, Myeloid, Acute

NCT06456463 2026-03-09

TRILLIUM

83 enrolled

Leukemia, Myeloid, Acute

NCT04128501 2026-03-06

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

LymphoidOther hematologic neoplasm

100 enrolled

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07060001 2026-03-06

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

Phase 2 Not yet recruiting

112 enrolled

Leukemia, Leukemia, Myeloid, Acute

NCT07392242 2026-03-06

A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

45 enrolled

Leukemia, Myeloid, Acute

NCT02530463 2026-03-05

Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

99 enrolled

Leukemia, Myelodysplastic Syndromes

NCT03683433 2026-03-05

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT07304011 2026-03-05

Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent

28 enrolled

Leukemia, Myeloid, Acute

NCT07148947 2026-03-04

Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

27 enrolled

Myeloid

Accelerated Phase Myeloproliferative Neoplasm

NCT06483906 2026-03-03

Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.

56 enrolled

Leukemia, Myeloid, Acute

NCT06511882 2026-02-27

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

37 enrolled

Leukemia, Myeloid, Acute

NCT03850418 2026-02-24

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

43 enrolled

Myeloid Malignancy

NCT06773208 2026-02-24

A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

30 enrolled

Leukemia, Myeloid, Acute

NCT03383575 2026-02-17

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

Classical hematologyOther hematologic neoplasm

63 enrolled

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05197426 2026-02-11

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

19 enrolled 24 charts

Leukemia, Myeloid, Acute

NCT03164057 2026-01-28

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

206 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03264404 2026-01-27

Azacitidine and Pembrolizumab in Pancreatic Cancer

Phase 2 Completed

36 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04891068 2026-01-14

BRE-04

40 enrolled

Breast

Breast Neoplasms

NCT04062266 2026-01-13

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

Hematologic Diseases, Leukemia, Myeloid, Acute

NCT04150029 2026-01-13

STIMULUS-AML1

Phase 2 Terminated

90 enrolled 26 charts

Leukemia, Myeloid, Acute

NCT05317000 2026-01-12

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05201066 2026-01-07

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

33 enrolled

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT06232655 2025-12-19

Cladribine Venetoclax in Monocytic AML

20 enrolled